FDA re­jects Melin­ta, Ve­na­torx’s UTI an­tibi­ot­ic over CMC is­sues

The FDA hand­ed a CRL to Melin­ta Ther­a­peu­tics and Ve­na­torx Phar­ma­ceu­ti­cals for their uri­nary tract in­fec­tion an­tibi­ot­ic, with the agency call­ing for more in­for­ma­tion on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER